Botulinum Toxin Type A Injections as Monotherapy for Upper Limb Essential Tremor Using Kinematics

Olivia Samotus, Niraj Kumar, Philippe Rizek, Mandar Jog

ABSTRACT: Background: There is a significant need for a targeted therapy for essential tremor (ET), as medications have not been developed specifically for ET, and the ones prescribed are often not well-tolerated, so that many patients remain untreated. Recent work has shown that, unlike previous experience, kinematically guided individualized botulinum toxin type A (BoNT-A) injections provide benefit along with minimal weakness. Ours is the first long-term (96-week) safety and efficacy study of BoNT-A as monotherapy for ET using kinematically driven injection parameters. Methods: Ten ET patients were administered six serial BoNT-A treatments every 16 weeks and were assessed at 6 weeks following treatment. During each study visit, the Fahn–Tolosa–Marin (FTM) scale, the Unified Parkinson’s Disease Rating Scale, and the Quality of Life for Essential Tremor Questionnaire (QUEST) were administered along with kinematic assessment of the treated limb. Participants performed scripted tasks with motion sensors placed over each arm joint. Dosing patterns were determined using the movement disorder neurologist’s interpretation of muscles contributing to the kinematically analyzed upper limb tremor biomechanics. Results: There was a 33.8% (p < 0.05) functional improvement (FTM part C) and a 39.8% (p < 0.0005) improvement in QUEST score at week 96 compared to pretreatment scores at week 0. Although there was a 44.6% (p < 0.0005) non-dose-dependent reduction in maximal grip strength, only 2 participants complained of mild weakness. Following the fourth serial treatment, mean action tremor score was reduced by 62.9% (p = 0.001) in the treated and by 44.4% (p = 0.03) in the untreated arm at week 96 compared to week 48. Conclusions: Individualized BoNT-A dosing patterns to each individual’s tremor modification provided an effective monotherapy for ET as function improved without functionally limiting muscle weakness.

RÉSUMÉ: Utilisation d’une monothérapie pour les tremblements essentiels des membres supérieurs : l’injection de toxine botulinique de type A au moyen de la cinématique. Contexte: Il existe un besoin réel pour un traitement ciblant les tremblements essentiels (TE) car les médicaments actuels n’ont pas été conçus précisément pour cette maladie neurologique. Ceux qu’on prescrit ne sont pas souvent très bien tolérés de sorte que de nombreux patients demeurent sans soins. Cela dit, une étude récente a montré, contrairement à une expérience menée antérieurement, que des injections de toxine botulinique de type A, à la fois individualisées et guidées cinématiquement, ont pu procurer des bénéfices à des patients sans que ces derniers ne ressentent une fatigue autre que minime. Notre étude est par ailleurs la première visant à évaluer à long terme (96 semaines) et au moyen de paramètres d’injection guidés cinématiquement la sécurité et l’efficacité de la toxine botulinique de type A à titre de monothérapie pour les TE. Méthodes: À toutes les seize semaines, on a administré un traitement de toxine botulinique de type A à dix patients atteints de TE, soit six traitements au total. Ces patients ont été ensuite évalués six semaines après chaque traitement. À l’occasion de chaque visite en lien avec notre étude, nous les avons soumis à divers outils d’évaluation: l’échelle clinique de Fahn–Tolosa–Marin (FTM), la Unified Parkinson’s Disease Rating Scale et un questionnaire mesurant la qualité de vie des patients atteints de TE (Quality of Life for Essential Tremor Questionnaire ou QUEST). Nous avons aussi procédé à une évaluation cinématique des membres traités. Munis d’un capteur de mouvement sur chaque articulation du bras, nos patients ont alors exécuté des tâches prédéterminées. Quant à la posologie, elle a été déterminée en tenant compte de l’avis d’un neurologue spécialisé des troubles du mouvement en regard des muscles responsables des tremblements affectant les membres supérieurs. Le tout a été ensuite analysé de façon cinématique et biomécanique. Résultats: En vertu de l’échelle de FTM (section C), on a observé une amélioration fonctionnelle de 33,8% (p < 0.05) ; en ce qui regarde le score au questionnaire QUEST, l’amélioration a été de 39,8% (p < 0.0005) à la 96e semaine en comparaison avec les scores de prétreatment à la semaine 0. Bien qu’on ait pu noter, peu importe la posologie administrée, une réduction de 44,6% (p < 0.0005) de la force de préhension maximale, seulement 2 patients se sont plaints de faiblesse légère aux membres supérieurs. À la suite du quatre traitement administré, le score moyen en matière de tremblements à la suite de l’exécution d’une tâche a été réduit de 62,9 % ( p = 0.001) dans le cas d’un membre traité et de 44,4 % ( p = 0.03) dans le cas d’un membre non-traité, et ce, en comparant la 96e semaine à la 48e. Conclusions: Une posologie individualisée de toxine botuliniques de type A adaptée à la biomécanique des tremblements affectant chaque individu a constitué une monothérapie efficace pour les TE. L’exécution de tâches par ces patients s’est ainsi améliorée sans que leur faiblesse musculaire ne s’aggrave.

Keywords: Essential tremor, Botulinum toxin type A, Kinematics, Biomechanics, Upper limb

doi:10.1017/cjn.2017.260

Can J Neurol Sci. 2018; 45: 11-22

From the Department of Clinical Neurological Sciences, London Health Sciences Centre, Lawson Health Research Institute, London, Ontario, Canada (OS, NK, PR, MJ); the Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada (OS, MJ).


Correspondence to: Mandar Jog, Department of Clinical Neurological Sciences, London Health Sciences Centre, Lawson Health Research Institute, 339 Windermere Road, A10-026, London, Ontario, Canada, N6A 5A5. Email: mandar.jog@lhsc.on.ca
**Introduction**

Essential tremor (ET) is the most common adult-onset movement disorder after restless legs syndrome. The prevalence of ET increases with age, affecting 2.3-14.3% of those aged 60 years and older. ET is diagnosed clinically based on the presence of a progressive action tremor involving the upper extremities (≥95%) and less commonly the head (≥34%), voice (≥12%), and lower extremities (30%), often resulting in significant physical and psychosocial disability. Treatment options currently available for ET include oral pharmacological agents, botulinum toxin A (BoNT-A) injection, and stereotactic surgery, including deep brain stimulation (DBS) and thalamotomy. As the basic neuroanatomy and neurotransmitter deficits in ET are largely unknown, no disease-specific drug is available, and all traditional oral agents used in treating ET were primarily developed for treatment of other diseases. Various drugs, including propranolol, the only pharmacotherapy approved through the U.S. Food and Drug Administration (FDA) to date, primidone, benzodiazepines, gabapentin, pregabalin, topiramate, and nimodipine are used in the treatment of ET, with an average tremor reduction of 50% or less. Poor efficacy is frequently coupled with dose-limiting side effects, such as drowsiness with primidone and bradycardia, syncope, fatigue, and erectile dysfunction with propranolol, and along with tolerance to the initial benefit, often leads to discontinuation of these drugs in 56.3% of patients. DBS of the ventral intermediate (VIM) nucleus of the thalamus may benefit patients with disabling ET, though only a fraction of patients are eligible for this highly invasive procedure that may produce lasting neurological side effects, including paresthesias (6-36%), dysarthria (3-18%), ataxia (6%), limb weakness (4-8%), balance disturbance (3-8%), and dystonia (2-9%). The efficacy and risks of gamma knife thalamotomy are comparable to VIM–DBS. Ultrasound-guided thalamotomy can be performed only unilaterally and again carries the same potential risks as gamma knife surgery, and thus large, randomized, controlled trials are required to assess the procedure’s efficacy and safety. A review of the current recommended treatment options for ET is summarized in Table 1. Thus, the use of BoNT-A, which improves both postural and kinetic tremor, appears to be an effective therapy to fulfill the significant unmet need in the treatment of ET faced by clinicians today.

While BoNT-A injection in the upper extremities is a viable treatment option for ET, limited functional efficacy due to dose-dependent wrist and finger muscle weakness remains a concern. The use of injection protocols involving fixed BoNT-A dosages and predetermined muscle sites, regardless of a patient’s unique tremor characteristics, are probable reasons for this problem. During tremor assessment, the characterization of the movement dynamics along the whole arm, muscle selection, dosing, and proper localization during injection are important considerations when utilizing BoNT-A to reduce functional disability caused by tremor with a minimal likelihood of weakness. While clinical knowledge and use of such technologies as electromyography (EMG) or ultrasound aid in muscle localization and injection, visually guided assessments to characterize tremulous movements at various joints are likely to fail due to the variability and complexity of tremor and the difficulty in accurately separating multijoint whole-arm movements. Thus, the lack of adequate tremor assessment tools and poor injection guidelines have limited the use of BoNT-A for ET.

The use of well-established kinematic technology for tremor characterization is a reliable and feasible methodology and can be used to accurately pinpoint tremulous muscle groups for BoNT-A therapy. Thus, kinematics provides an individualized multitarget movement pattern that can reduce the likelihood of dose-dependent weakness and thereby improve the functional efficacy of BoNT-A for ET. Recent work from our pilot studies has demonstrated the efficacy and tolerability of three serial kinematic-guided BoNT-A treatments for ET and PD tremor. Due to the lack of efficacy of the available medications for ET and their systemic adverse effects, ET patients were reluctant to take them as a first-line therapy and thus chose to receive BoNT-A injections. This article reports the first and longest open-label study on the efficacy and safety of monotherapy BoNT-A in 10 ET patients who received 6 BoNT-A injection treatments based upon kinematically guided muscle selection criteria for upper-limb ET tremor every 16 weeks over a 96-week period.

**Methods**

The following methodology has been previously described. This was an open-label, single-center, single-injector pilot study reporting on 10 of the total convenience sampling of 25 ET participants recruited from the London Movement Disorders Centre in London, Ontario, Canada. The Western University Health Sciences Research Ethics Board approved this clinical phase Ib pilot study protocol, and the study and other studies involving this intervention are registered (ClinicalTrials.gov: NCT02427646). The study protocol included ET participants who were naïve to BoNT-A and oral medications or those reluctant to use oral medications as a first-line therapy and thus chose to receive BoNT-A injections. All therapeutic options were presented to the participants. From the total of 24 ET participants included in this open-label study, 10 ET participants were naïve to both BoNT-A and oral medications. These 10 participants provided written consent and were chosen for analysis, as they were naïve to all ET oral medications. The study’s progress is outlined in the CONSORT flowchart depicted in Figure 1. The first visit of the first participant and the last visit of the final participant occurred in April of 2012 and May of 2015, respectively.

BoNT-A injection treatments were administered every 16 weeks starting at week 0, with a follow-up study visit occurring 6 weeks postinjection, for a total of 13 study visits over 96 weeks. Participants who were naïve to medication maintained monotherapy with BoNT-A injections for their tremor throughout the duration of the study. Participants were assessed at approximately the same time of day for all visits. Each visit included completing clinical rating scales and kinematic assessment of upper-limb tremor. The tremor-dominant limb was treated with BoNT-A (incobotulinumtoxinA; Xeomin, Merz Pharma, Frankfurt, Germany) under EMG guidance, using a Clavis (Natus Medical Inc., San Diego, California, USA) portable EMG device, with a 1”-long 30-gauge injectable EMG needle (0.5 mL of saline per 100-unit vial dilution to minimize liquid volume and therefore spread of BoNT-A). The kinematic device has been approved by the FDA and Health Canada for use in clinical trials and is being commercialized. The average time per arm for kinematic assessment is 15 minutes.
tremor-inducing side effects.

Participants included in the study were consenting males and females diagnosed with ET as their primary and functionally impairing symptom, aged 18 to 80 years, and naïve to BoNT-A and any oral antitremor medications. Participant criteria excluded those who had a history of stroke, had contraindications per the incobo- 

Table 1: Current, recommended treatment options for ET

<table>
<thead>
<tr>
<th>Drug name</th>
<th>Drug class</th>
<th>Level/class</th>
<th>Total daily dosage (mg/d)</th>
<th>Sample size</th>
<th>Efficacy (compared to baseline)</th>
<th>Adverse effects</th>
<th>Review reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propranolol</td>
<td>Beta blocker</td>
<td>A</td>
<td>40-320</td>
<td>533</td>
<td>–50% of patients respond. Those that respond experience a 50-60% reduction in tremor</td>
<td>Nausea, vomiting, bradycardia, diarrhea, hypotension, drowsiness, fatigue, light-headedness, weakness, and paresthesia</td>
<td>29, 31</td>
</tr>
<tr>
<td>Primidone</td>
<td>Anticonvulsant</td>
<td>A</td>
<td>50-1000</td>
<td>218</td>
<td>50% mean improvement rated by clinical scales and accelerometry</td>
<td>Ataxia, vertigo, nausea, vomiting, fatigue, malaise, dizziness, unsteadiness, confusion, impotence, rash</td>
<td>29-31</td>
</tr>
<tr>
<td>Atenolol</td>
<td>Beta blocker</td>
<td>B</td>
<td>50-150</td>
<td>79</td>
<td>25% mean improvement by clinical scales, 37% mean improvement by accelerometry</td>
<td>Light-headedness, nausea, cough, dry mouth, sleepiness, decreased pulse and blood pressure</td>
<td>29, 30</td>
</tr>
<tr>
<td>Alprazolam</td>
<td>Benzodiazepine</td>
<td>B</td>
<td>0.125-3</td>
<td>46</td>
<td>25-37% mean improvement by clinical scales</td>
<td>Mild sedative and fatigue effects</td>
<td>29, 30</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>Anticonvulsant</td>
<td>B</td>
<td>1200-1800</td>
<td>61</td>
<td>33% improvement by clinical scales, 77% improvement by accelerometry</td>
<td>Drowsiness, fatigue, dizziness, nervousness, shortness of breath, reduced libido</td>
<td>29-31</td>
</tr>
<tr>
<td>Sotalol</td>
<td>Beta-adrenergic receptor antagonist</td>
<td>B</td>
<td>75-240</td>
<td>50</td>
<td>28% mean improvement in clinical scales</td>
<td>Serious ventricular arrhythmias, dose-related QT interval prolongation, reduced alertness</td>
<td>7, 29, 30</td>
</tr>
<tr>
<td>Topiramate</td>
<td>Anticonvulsant</td>
<td>B</td>
<td>25-300</td>
<td>335</td>
<td>29% improvement in clinical scales (mean dose = 292 mg/d); 30% improvement in tremor (up to 400 mg/d) with a 32% attrition rate due to adverse events</td>
<td>Dizziness, disorientation, paresthesia, weight loss, memory difficulty, appetite suppression, cognitive difficulties, upper respiratory tract infection, taste perversion, fatigue, nausea, headache, somnolence</td>
<td>30, 31</td>
</tr>
<tr>
<td>Nimodipine</td>
<td>Calcium channel blockers</td>
<td>C</td>
<td>120</td>
<td>16</td>
<td>45% improvement by clinical scales and 53% improvement by accelerometry (n = 14)</td>
<td>Headache, heartburn, hypotension</td>
<td>29, 30</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>Benzodiazepine</td>
<td>C</td>
<td>0.5-6</td>
<td>44</td>
<td>45% improvement by accelerometry</td>
<td>Drowsiness, depression, cognitive and behavioral impairments</td>
<td>29, 30</td>
</tr>
<tr>
<td>BoNT-A (monotherapy)</td>
<td>Neurontoxin</td>
<td>C</td>
<td>50-300 U/arm</td>
<td>283</td>
<td>20-27% improvement by clinical scales (n = 133)</td>
<td>Dose-dependent muscle weakness occurred in 30% of patients, reduced grip strength, stiffness, cramping, pain at injection site</td>
<td>29, 30, 35</td>
</tr>
<tr>
<td>Deep brain stimulation</td>
<td>Unilateral or bilateral VIM-DBS; STN-DBS</td>
<td>C</td>
<td>398</td>
<td>50-90% improvement by clinical scales up to 3 years; chronic stimulation gradually worsens efficacy, leading to loss of tremor suppression in about 70% of patients</td>
<td>Dysarthria, disequilibrium, paresthesias, weakness, headache, intracranial hemorrhage, subdural hemorrhage, lead dislodgement, generalized motor seizures; about 18% experience equipment malfunction or lead displacement</td>
<td>29, 35</td>
<td></td>
</tr>
<tr>
<td>Thalamotomy</td>
<td>Gamma knife; MRI-guided focused ultrasound</td>
<td>C</td>
<td>181</td>
<td>55-90% improvement by clinical scales</td>
<td>Hemiparesis, transient problems with speech, motor function, dysarthria, verbal/cognitive deficit, weakness, confusion, facial paresis; about 7% experience permanent complications (hemorrhage and infection).</td>
<td>8, 29, 30</td>
<td></td>
</tr>
</tbody>
</table>

Levels of evidence are derived from the American Academy of Neurology recommendations: A = established effective, B = probably effective, C = possibly effective, U = data inadequate or conflicting.

Study Eligibility Criteria

Severity of tremor, overall quality of life (QoL), and functional disability caused by tremor were measured using well-established rating scales. QoL was scored using the Quality of Life for Essential Tremor Questionnaire (QUEST), and tremor severity and functional ability were assessed by the Fahn–Tolosa–Marin (FTM) scale for each participant per study visit. The Unified Parkinson’s Disease Rating Scale (UPDRS) part III (motor examination), items 20 and 21, rest and action tremor,
respectively, were completed by a movement disorders neurologist, blinded to prior results, during injection visits. The tolerability to BoNT-A was monitored by assessing muscle weakness using a Baseline® hydraulic hand dynamometer (item no. 12-0240, Fabrication Enterprises, White Plains, New York, USA) to measure maximal grip strength. Additionally, participants reported any perceived muscle weakness using a Likert-type scale (ranging from 0 = no, 1 = mild, 2 = moderate, 3 = marked, to 4 = severe weakness in injected muscles) between study visits. Manual muscle testing (MMT) was used to assess finger flexor/extensor muscles where scores ranged from 0, 1, 2–, 2, 2+, 3–, 3, 3+, 4–, 4, 4+, to 5, with a score of 3+ or higher representing the ability to hold muscle position against gravity and resist slight pressure.

**Figure 1:** CONSORT 2010 flow diagram showing the design and progress of the reported study.

Kinematic Tremor Assessment

Participants performed a series of scripted tasks while seated with motion sensor devices placed over each arm joint (Figure 2). Goniometers (SG150, Biometrics Ltd., Chester, UK) were placed over the wrist, measuring flexion/extension (F/E) and radial/ulnar (R/U) movement; over the elbow, measuring F/E; and over the shoulder joint, measuring F/E and abduction/adduction (Ab/Add) deviations. A torsiometer (Q150, Biometrics) was placed over the forearm to measure pronation/supination (P/S) deviations about the wrist. A total of four motion sensors were required to capture movement from each joint. A TeleMyo™ 2400T transmitter with MyoResearch XP Master Edition 1.08.09 (Noraxon®, Scottsdale, Arizona, USA) was used to collect motion sensor data.

Four scripted tasks designed to capture tremor composition during two postural tasks ("posture-1" and "posture-2") and two weight-bearing tasks ("load-1" and "load-2") are depicted in Figure 3. The postural tasks included "posture-1," having participants place their arms out in front of their body with palms facing downward and "posture-2," with their palms facing inward. The weight-bearing tasks, "load-1" and "load-2," involved participants holding an empty and weight-bearing (1-pound weight) cup, respectively. Custom-written software in MatLab® (v. 2011a; MathWorks, Natwick, Massachusetts, USA) was used to process raw sensor angular data.
displayed tremor severity at each arm joint represented as total angular root mean square (RMS) amplitude for each task. Total tremor at the wrist and shoulder joints were further segmented by the amount of tremor, represented as a percentage of the overall tremor, present in each degree of freedom (DOF) that the joint moves in. Such tremor segmentation was denoted “percent contribution of tremor.”

Determination of BoNT-A Injection Parameters

A similar injection determination protocol to that performed by Samotus and Rahimi et al. was utilized. Extracted tremor kinematic data were presented to the movement disorders neurologist prior to injection. Solely using kinematic tremor data, BoNT-A injection parameters were determined for each joint. The total tremor amplitude at each joint was utilized to determine an appropriate BoNT-A dose per joint required to minimize tremor using the injector’s best clinical judgment. The total dose allocated to each joint was divided for individual degrees of freedom for each joint using the percent contribution kinematic data, except for the elbow, which moves in one DOF (F/E) and was not segmented further. Muscles targeted for treatment were selected based on the known anatomical basis of movement. Muscles associated with F/E and R/U wrist deviations (including the flexor carpi radialis, flexor carpi ulnaris, extensor carpi radialis, and extensor carpi ulnaris) and P/S deviations (including the pronator teres, pronator quadratus, and supinator) were targeted when tremor about the wrist was detected. The biceps and triceps were treated when elbow tremor was detected, and the pectoralis major, supraspinatus, deltoid, and teres major were targeted to treat F/E and Abd/Add shoulder tremors. The kinematic tremor results from pre-
postinjection visits were compared by the injector to determine whether dosages or muscle sites required modification.

Statistical Analysis

The IBM SPSS statistical software package (v. 21; SPSS Inc., Chicago, Illinois, USA) was employed to analyze the clinical and kinematic data to determine any statistically significant differences across all timepoints. The mean angular RMS tremor amplitude over three trials during each scripted task was calculated at each timepoint and log-transformed as RMS amplitude positively generated skewed distributions. The Shapiro–Wilk test, skewness, and kurtosis z-scores were used to test normality for parametric testing. The datasets did not satisfy the parametric criteria and were subjected to Friedman’s test, a nonparametric instrument. Significant mean differences with post-hoc Bonferroni corrections for multiple comparisons were performed between week 0 (pre-treatment) and all subsequent posttreatment timepoints, between peak effect timepoints (weeks 6-22-38-54-70-86) and between reinjection timepoints (weeks 0-16-32-48-64-80-96) and within each injection cycle (first treatment: weeks 0-6-16; second treatment: weeks 6-22-32; third treatment: weeks 32-38-48; fourth treatment: weeks 48-54-64; fifth treatment: weeks 64-70-80; sixth treatment: weeks 80-86-96) within the participant population in clinical datasets and kinematic log-transformed datasets.

RESULTS

Participant Demographics

The demographics and baseline clinical rating scores of the 10 ET participants naïve to antitremor medications are summarized in Table 2a. At week 86, one participant (1/10; 10%) could not continue due to a fatality resulting from renal failure, unrelated to tremor or the study intervention.

Table 2b and Supplemental Table 1 (see Supplementary Materials) outline the total mean dose and number of muscles injected and the dosages per muscle for each injection cycle per participant, respectively. In addition, Supplemental Table 2 (see Supplementary Materials) outlines the mean and range of BoNT-A dosages utilized over all six treatments for all participants. Participants (n = 10) were injected in their most bothersome limb as perceived by the participant, and the mean total dose for the first injection was 185.5 ± 37.1 units in 9.6 ± 1.7 muscles (Table 2b). BoNT-A injections remained unchanged and thus were optimized for the second treatment in four participants (40%). By the third treatment, 60% of participants met the criteria for a satisfactory therapeutic response, and their parameters remained unchanged. Between weeks 32 and 80, 30% of participants (ID nos. 1, 3, and 8) required no changes to their parameters; 30% of participants required an increased dose, as ID4 experienced suboptimal benefit, and ID5 and ID7 were experiencing functional benefit and wanted to eliminate tremor for fine motor tasks. A reduction in dose was required for 40% of participants, based on participant feedback, to minimize lasting weakness in injected muscles, specifically the flexor carpi radialis/ulnaris (FCR/FCU) for wrist flexion weakness and the extensor carpi radialis/ulnaris (ECR/EUC) for wrist extension and grip strength weakness.

FCR and FCU dosages were reduced from a mean of 14.1 ± 4.4 U for the first treatment to 11.4 ± 4.9 U for the third treatment. Reductions in ECR and ECU dosages were applied later in the treatment course from a mean of 16.9 ± 5.2 U for the first treatment to 13.8 ± 5.1 U for the sixth treatment. Dosages applied to the pronators, supinator, biceps, triceps, and shoulder muscles remained relatively constant over the treatment course.

Table 2a: Demographics of ET study participants and baseline UPDRS, QUEST, and FTM parts A–C scores

<table>
<thead>
<tr>
<th>ID</th>
<th>Gender</th>
<th>Age</th>
<th>Motor-dominant arm</th>
<th>Injected arm</th>
<th>Arm circumference (cm)</th>
<th>Weight (lbs)</th>
<th>Rest tremor (FTM part A)/4</th>
<th>Postural tremor (FTM part A)/4</th>
<th>Action tremor (FTM part A)/4</th>
<th>Functional disability (FTM part C)/28</th>
<th>QUEST score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>67</td>
<td>R</td>
<td>R</td>
<td>38</td>
<td>270</td>
<td>2</td>
<td>4</td>
<td>2</td>
<td>14</td>
<td>39</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>64</td>
<td>R</td>
<td>R</td>
<td>27</td>
<td>120</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>21</td>
<td>49</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>71</td>
<td>R</td>
<td>R</td>
<td>29</td>
<td>140</td>
<td>1</td>
<td>4</td>
<td>0</td>
<td>10</td>
<td>48</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>82</td>
<td>R</td>
<td>L</td>
<td>26</td>
<td>120</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>15</td>
<td>22</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>65</td>
<td>R</td>
<td>R</td>
<td>37</td>
<td>270</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>12</td>
<td>42</td>
</tr>
<tr>
<td>6</td>
<td>F</td>
<td>80</td>
<td>R</td>
<td>R</td>
<td>27</td>
<td>130</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>17</td>
<td>64</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>73</td>
<td>R</td>
<td>R</td>
<td>36</td>
<td>200</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>12</td>
<td>22</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>84</td>
<td>R</td>
<td>R</td>
<td>32</td>
<td>175</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>20</td>
<td>39</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>59</td>
<td>R</td>
<td>R</td>
<td>38</td>
<td>227</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>11</td>
<td>31</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>72</td>
<td>L</td>
<td>L</td>
<td>36</td>
<td>237</td>
<td>0</td>
<td>3</td>
<td>2</td>
<td>19</td>
<td>30</td>
</tr>
<tr>
<td>Mean</td>
<td>4M</td>
<td>71.7</td>
<td>1 L</td>
<td>2 L</td>
<td>32.6</td>
<td>188.9</td>
<td>1</td>
<td>2.2</td>
<td>1.6</td>
<td>15.1</td>
<td>38.6</td>
</tr>
<tr>
<td>± SD</td>
<td></td>
<td>8.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.9</td>
<td>13.1</td>
</tr>
<tr>
<td>Median</td>
<td></td>
<td>71.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14.5</td>
<td>39</td>
</tr>
<tr>
<td>Range (low)</td>
<td></td>
<td>59</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10</td>
<td>22</td>
</tr>
<tr>
<td>Range (high)</td>
<td></td>
<td>84</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>21</td>
<td>64</td>
</tr>
</tbody>
</table>

ET = essential tremor; F = female; FTM = Fahn–Tolosa–Marin tremor rating scale; L = left; M = male; QUEST = Quality of Life for Essential Tremor Questionnaire; R = right; SD = standard deviation of the population; UPDRS = Unified Parkinson’s Disease Rating Scale.
Total dose of BoNT-A is represented by dosage units and is in BoNT-A/incobotulinumtoxinA units.

Wrist tremor severity during week 96 (0.1 weeks 32, 48, 64, 80, and 96) to a barely perceivable tremor at treatment, which was maintained at each reinjection timepoint (at reduction in tremor was observed following the second treatment, with a mean difference a significantly longer-lasting effect on mean wrist postural tremor severity captured during task post-BoNT-A treatments was conducted by kinematic tremor reduction in tremor was significantly reduced \( \chi^2(12) = 23.438, p = 0.024 \) from a mean severity of 0.6 ± 0.7 RMS (median = 0.2) at week 0 to 0.3 ± 0.6 RMS (median = 0.04, \( p = 0.02 \)) at week 6, though tremor severity was not significantly different at week 16 (median = 0.1, \( p = 0.4 \)). BoNT-A intervention produced a significantly longer-lasting effect on mean wrist postural tremor following the second treatment, with a mean difference of 0.4 ± 0.2 RMS at week 32 (\( p = 0.02 \)) compared to week 0. Following the second treatment, wrist tremor in “posture-1” was reduced even further from 0.3 ± 0.5 at week 16 (median = 0.1) to 0.1 ± 0.2 at week 64 (median = 0.05, \( p = 0.04 \)). Wrist tremor amplitude during peak effect of BoNT-A was significantly reduced following the third injection at week 38 to weeks 54 and 80 (Figure 4a). Mean significant reduction in elbow tremor during “posture-2” was reported \( \chi^2(12) = 23.308, p = 0.025 \) from week 0 (median = 0.2) at week 6 (median = 0.07, \( p = 0.037 \)) and was maintained at week 80 (median = 0.06, \( p < 0.0005 \)). Mean elbow tremor was further significantly reduced between weeks 16 and 80 (46.5% change) and between weeks 80 and 96 (40.1% change). Change in tremor severity was not significantly different in the shoulder joint \( \chi^2(12) = 18.264, p = 0.108 \) over all scripted tasks over the treatment course (data not shown).

Kinematic Efficacy

Objective monitoring of the change in tremor severity pre- and post-BoNT-A treatments was conducted by kinematic tremor assessments for each participant. Illustrated in Figure 4a, mean wrist postural tremor severity captured during task “posture-1” produced a statistically significant difference \( \chi^2(12) = 23.438, p = 0.024 \) from a mean severity of 0.6 ± 0.7 RMS (median = 0.2) at week 0 to 0.3 ± 0.6 RMS (median = 0.04, \( p = 0.02 \)) at week 6, though tremor severity was not significantly different at week 16 (median = 0.1, \( p = 0.4 \)). BoNT-A intervention produced a significantly longer-lasting effect on mean wrist postural tremor following the second treatment, with a mean difference of 0.4 ± 0.2 RMS at week 32 (\( p = 0.02 \)) compared to week 0. Following the second treatment, wrist tremor in “posture-1” was reduced even further from 0.3 ± 0.5 at week 16 (median = 0.1) to 0.1 ± 0.2 at week 64 (median = 0.05, \( p = 0.04 \)). Wrist tremor amplitude during peak effect of BoNT-A was significantly reduced following the third injection at week 38 to weeks 54 and 86, following the fourth and sixth treatments. Likewise, mean wrist tremor was significantly reduced \( \chi^2(12) = 31.232, p = 0.002 \) in “posture-2” from 1.0 ± 0.8 (median = 0.9) at week 0 to 0.2 ± 0.3 (median = 0.1, \( p = 0.003 \)) at week 6. A greater reduction in tremor was observed following the second treatment, which was maintained at each reinjection timepoint (at weeks 32, 48, 64, 80, and 96) to a barely perceivable tremor at week 96 (0.1 ± 0.06; median = 0.09, \( p < 0.0005 \)) (Figure 4a).

Clinical Efficacy

Severity of action tremor, rated by mean UPDRS item 21 score, was statistically significantly reduced \( \chi^2(6) = 20.681, p = 0.002 \) from 2.7 ± 0.6 (median = 3.0) at week 0 to 1.9 ± 0.9 at week 48 (median = 1.0, \( p = 0.03 \)) following the fourth treatment (Figure 4b). Mean item 21 score was significantly reduced from 2.7 ± 0.6 (median = 3.0) at week 0 to 1.9 ± 0.9 at week 48 (median = 1.0, \( p = 0.03 \)) following the fourth treatment (Figure 4b). Mean item 21 score was significantly reduced from 2.7 ± 0.6 (median = 3.0) at week 0 to 1.9 ± 0.9 at week 48 (median = 1.0, \( p = 0.03 \)) following the fourth treatment (Figure 4b). Mean item 21 score was significantly reduced from 2.7 ± 0.6 (median = 3.0) at week 0 to 1.9 ± 0.9 at week 48 (median = 1.0, \( p = 0.03 \)) following the fourth treatment (Figure 4b). Mean item 21 score was significantly reduced from 2.7 ± 0.6 (median = 3.0) at week 0 to 1.9 ± 0.9 at week 48 (median = 1.0, \( p = 0.03 \)) following the fourth treatment (Figure 4b).
UPDRS item 21 rating of the untreated arm was significantly reduced following the fourth treatment at week 48 [$\chi^2(3) = 8.561, p = 0.036$] from $1.9 \pm 0.9$ (median = 2.0) to $1.5 \pm 1.1$ (median = 1.5, $p = 0.04$) at week 64 and to $1.3 \pm 1.2$ (median = 1.0, $p = 0.03$) at week 80.

FTM part A assessed tremor severity during posture and action positions are illustrated in Figure 4c. Mean postural tremor was statistically significantly reduced [$\chi^2(12) = 27.591, p = 0.006$] from $2.2 \pm 1.3$ (median = 2.0) at week 0 to $0.7 \pm 0.8$ FTM points at week 32 (median = 0.5, $p = 0.01$), and at the time of reinjection and tremor reduction it was maintained at week 96 (median = 0, $p = 0.005$). Significant improvement in postural tremor was observed at each peak effect of BoNT-A timepoints between week 6 and weeks 22, 38, 54, 70 and 86, resulting in a mean postural tremor severity of $0.3 \pm 0.5$ FTM points (median = 0, $p = 0.008$) at week 86. Mean severity of action tremor was reduced [$\chi^2(12) = 14.730, p = 0.02$] from $1.60 \pm 0.9$ (median = 1.5) to $0.7 \pm 0.8$ FTM points at week 96 (median = 0.5), though this was not statistically significant. There was no significant difference in mean rest tremor over the treatment course [$\chi^2(12) = 10.570, p = 0.556$], attributed to only 30% of ET participants (3/10) experiencing rest tremor with an FTM score of 2 or higher.

Functional disability caused by tremor was rated by subcategories in FTM part C (Figure 4d). Eating solid foods was significantly improved [$\chi^2(12) = 27.860, p = 0.006$] by observing a reduction in mean FTM part C subscore from $2.3 \pm 0.5$ (median = 2.0) at week 0 to $1.7 \pm 0.8$ FTM points at week 6 (median = 2.0, $p = 0.05$) following the first treatment, and improvements in eating performance continued to week 96, compared to week 0, by observing a mean of $1.6 \pm 0.9$ FTM points (median = 2.0, $p = 0.04$). Ability to eat significantly improved between the second and fifth injections at weeks 22 and 70 ($p = 0.05$). Ability to drink liquids was significantly improved [$\chi^2(12) = 27.557, p = 0.006$] from $2.8 \pm 0.6$ (median = 3.0) at week 0 to $1.5 \pm 1.2$ FTM points at week 6 (median = 1.5, $p = 0.008$). An even greater improvement in drinking ability was achieved following the second treatment at week 22 to week 86 by observing a mean FTM part C subscore of $1.3 \pm 0.9$ (median = 1.0, $p = 0.03$) and following the third treatment at week 32 to week 80, yielding a mean FTM part C drinking score of $1.6 \pm 0.8$ (median = 1.0, $p = 0.02$). Additionally, the ability to perform hobbies and/or work activities was significantly improved [$\chi^2(12) = 23.017, p = 0.028$] from $2.6 \pm 0.8$ (median = 3.0) at week 0 to $1.2 \pm 1.0$ FTM points (median = 1.0, $p = 0.02$) at week 6, which was maintained over the study course to a mean score of $1.6 \pm 0.5$ FTM points at week 96 (median = 2.0, $p = 0.05$), indicating a change from a marked to mild interference due to ET. FTM part C subcategory for ability to socialize was significantly improved following the fourth treatment at week 48 to week 86 [$\chi^2(12) = 21.101, p = 0.049$]. FTM subcategories for hygiene, dressing, speaking, and writing remained statistically unchanged over the treatment course, as these tasks were not functionally impaired by tremor.

Relief of arm tremor severity and functional improvements in activities of daily living was accompanied by a statistically significant improvement [$\chi^2(12) = 33.583, p = 0.001$] in QoL, rated by mean QUEST score (Figure 4e). Mean QUEST score was significantly reduced from $38.6 \pm 13.1$ (median = 39.0) at week 0 to $26.7 \pm 12.7$ (median = 24.0, $p = 0.032$) at week 6. An even greater improvement in QoL was achieved following the third treatment between week 38 and weeks 70 and 86, resulting in a mean QUEST score of $23.4 \pm 14.0$ (median 21.0, $p = 0.03$). QoL scores were further reduced following the fourth treatment at week 48 and were maintained throughout the study to $23.3 \pm 11.6$ (median = 23.5, $p < 0.0005$) at week 96.

With improvements in tremor amplitude and arm function, there was a reduction in maximal muscle strength [$\chi^2(12) = 40.135, p < 0.0005$] that coincided with peak effect of BoNT-A (Figure 4f). Maximal grip strength was significantly reduced from $27.3 \pm 12.3$ (median = 22.3) at week 0 to $20.4 \pm 16.1$ kg force (median = 15.8, $p = 0.004$) at week 6, which returned to a mean grip strength of $21.9 \pm 11.1$ (median = 17.0, $p = 0.5$) at week 16. The change in grip strength did not indicate a lasting negative effect on arm function (Figure 4f), as participants experienced a mean Likert score of patient-reported perceived weakness [$\chi^2(12) = 28.244, p = 0.005$] of $1.1 \pm 1.1$ (median = 1.0, $p = 0.3$) at week 6 and $0.5 \pm 0.8$ (median = 0, $p = 0.5$) at week 16, indicating an absence of to mild weakness in injected muscles 16 weeks following the first treatment. However, following the fourth treatment at week 54, 70% of participants (7/10) experienced moderate weakness in injected muscles and had mean Likert scores of $1.6 \pm 0.9$, which was reduced to $0.8 \pm 0.8$ at week 64 in 60% of participants (6/10). This warranted a reduction in dose for the fifth treatment, which ultimately reduced the severity of any lasting weakness from $1.6 \pm 0.9$ at week 70 to $0.2 \pm 0.4$ at week 80 without affecting efficacy or functional improvements. Although there was a 44.6% ($p < 0.0005$) non-dose-dependent reduction in maximal grip strength at week 96, only 2 participants complained of mild weakness, resulting in a mean Likert score of $0.3 \pm 0.5$ (median = 0.0, $p = 0.7$).

The MMT assessed loss of strength present in injected muscles. At 6 weeks following a treatment, one or two participants experienced a score of 3 (fair) or lower in the wrist, though weakness in injected muscles was not present at reinjection visits until week 80 for one participant (10%) at the sixth treatment visit (Supplemental Figures 1-2; see Supplementary Materials). One participant experienced a reduction in elbow flexion and extension strength at week 86 following the sixth injection, though this was not present at week 96 (data not plotted). MMT testing for finger flexors in the treated arm showed minimal changes in strength over the total 96-week duration. Some 8 participants experienced finger extensor weakness following the fifth injection at week 70, though lasting finger extensor weakness was not present in 6 participants (MMT score ≥3), as 2 participants.
experienced mild weakness (MMT score ≤3) at week 80. As finger muscles were not treated with BoNT-A, any weakness in those muscle groups was attributed to spread of toxin.

**DISCUSSION**

BoNT-A use has been proven to be an effective localized therapy by reducing tremor severity with a low incidence of muscle weakness, thereby improving arm functionality interfered by tremor.\(^13\)\(^-\)\(^15\) Such improvements have been attributed to the ability of kinematic technology to accurately pinpoint tremulous joints that contribute to ET and to individualize BoNT-A patterns, which past studies had not utilized.\(^10\)\(^-\)\(^11\),\(^25\)\(^-\)\(^27\) These studies used fixed dosages of BoNT-A into predetermined/randomized muscle groups, thus not an individualized approach, which failed to achieve significant functional improvements, despite at least a 50% reduction in tremor, due to lasting transient muscle weakness; hence, past studies were limited to one or two injection cycles.\(^10\)\(^-\)\(^11\),\(^20\) In addition, clinicians and patients are unenthusiastic about using oral medications as first-line therapy, as patients frequently experience significant adverse events that prompt discontinuation of pharmacotherapy, and approximately a third of patients are secondary nonresponders, as outlined in Table 1.\(^3\)\(^,\)\(^7\)\(^,\)\(^25\)\(^-\)\(^28\) Thus, effective long-term management of ET is a significant unmet need that stresses the necessity for more targeted treatments available to patients, such as BoNT-A injections. This study is the longest open-label study to demonstrate functional improvement by efficacious and safe management of ET over six serial BoNT-A monotherapy treatments in a cohort of participants.

Kinematics provided an objective output of the dynamics of tremor acting at each arm joint, which in turn was utilized by the injector to choose appropriate dosages to allocate to muscles generating the tremulous movements, previously described by Samotus, Rahimi, and colleagues.\(^13\)\(^,\)\(^15\) This standardized method of assessing tremor personalized initial BoNT-A parameters to each participant’s unique tremor signature and permitted long-term objective monitoring for optimization of BoNT-A dosing. Significant improvement in tremor was achieved by focal BoNT-A monotherapy following just one treatment at weeks 6 and 16 (Figure 4), and similar improvements by clinical scales and accelerometry measures of tremor were achieved by level A antitremor medications—primidone and propranolol (Table 1).\(^7\)\(^,\)\(^14\)\(^,\)\(^15\),\(^26\)\(^-\)\(^28\) However, treatment abandonment rates due to dose-dependent undesirable effects by oral medications is as high as 55% and generally occurs within the first 3 months of treatment.\(^30\),\(^32\) Studies evaluating the long-term efficacy of oral agents have reported that at the end of the first year of treatment patients experienced a 10 to 25% global improvement in tremor symptoms.\(^30\),\(^32\) Our work has demonstrated that tremor relief by BoNT-A as a monotherapy significantly improves with each serial treatment, producing 74.5 and 77.3% improvements in postural tremor at week 48 and 96, respectively. Interestingly, action tremor (UPDRS item 21) in the untreated arm was significantly reduced after the fourth treatment, between weeks 48 and 64, and between weeks 48 and 80, though it was not significantly different between weeks 48 and 96 (Figure 4b). Contralateral BoNT-A effects may be attributed to altered spindle afferent inflow directed to spinal motoneurons,\(^33\) though further studies are needed to investigate the central modulatory effects of BoNT-A. The ability to personalize and tailor therapy to the dynamic variation of tremor during long-term management of ET is significantly lacking with oral pharmacological agents (outlined in Table 1), as more than 50% of patients discontinue oral ET therapy due to lack of effect and significant adverse events.\(^26\)\(^-\)\(^28\)

Significant functional improvement in activities of daily living tasks (such as eating and drinking), work activities, hobbies, and socializing activities was coupled with significant improvement in QoL scores. Similarly, the effective perceived weakness was minimal and when present was alleviated by dose optimization without loss of efficacy. The change in maximal grip strength did not indicate a lasting negative effect on arm function, as participants perceived any loss in arm strength as mild to moderate 6 weeks following a treatment. A loss in maximal grip strength by more than 20% is the smallest difference in grip strength that can be perceived by a participant and is mainly attributed to impairment in wrist flexor and extensor muscle groups.\(^24\),\(^34\) Reported from the wrist flexor/extensor MMT assessments, just 10 to 20% (n = 1 or 2) of participants rated a score of 3 (fair) or lower during peak effect of BoNT-A that was diminished at reinjection, demonstrating no negative lasting or functional wrist weakness over the six treatments. Supplemental Figure 2 (see Supplementary Materials) illustrates the number of participants who scored an MMT rating of ≥3 focusing on finger flexors, extensors, abduction, adduction, and wrist flexion and extension muscles plotted with mean perceived weakness Likert scores. This demonstrates a trend with a greater perceivable weakness (mean Likert score of 1.5, indicating mild to moderate perceivable weakness) by participants, peaking at week 70, and may be attributed to an increase in weakness originating from the finger extensor muscle groups, which were not injected, and thus is a result of spread of toxin. It should be noted that finger extensor weakness (MMT ≤3) was not long lasting for 6 of 8 participants at reinjection (week 80), and this is also demonstrated by the drop in mean Likert score to 0.2 (slight weakness). These results highlight the benefits of individualization of therapy with kinematics and are credited to the ability of kinematics to personalize injection patterns to each participant’s tremor features.

The limitations of our study include a lack of a treatment comparator and nonblinded injections. Blinded studies are challenging with BoNT-A, as muscle weakness is easily perceived by both investigators and participants.\(^27\) A persistent placebo response is unlikely, as this is a longitudinal study where outcomes are objectively determined. Additionally, crossover study designs are complex, as a true baseline in tremor severity is challenging to determine in previously treated participants. The lack of tolerability and efficacy of visually based BoNT-A patterns have been extensively reported in the literature,\(^10\)\(^-\)\(^12\),\(^25\)\(^-\)\(^27\) and thus the effects of visually based versus kinematically based BoNT-A patterns were not compared. The study’s sample size was smaller than in some of the previous literature,\(^11\),\(^26\) as the cohort of participants was specifically those patients who were never treated with any medications.\(^15\) Participants were assessed at the same time of day to reduce fluctuations in severity at each visit.

Kinematic characterization of upper-limb ET was pivotal for identifying appropriate BoNT-A dosages and muscle groups to inject for each participant. Over the two-year period of serial treatments, participants achieved stable management of their tremor and functional benefit with minimal side effects, which was not achievable with pharmacotherapy alone. Kinematic technology has made personalized BoNT-A injection patterns and optimization of longitudinal management of ET with monotherapy possible.
ACKNOWLEDGMENTS

We would like to acknowledge the contribution of the participants and by the postdoctoral engineering and volunteer research staff at the National Parkinson Foundation Centre of Excellence, London Movement Disorder Centre, located within the London Health Sciences Centre, London, Ontario, Canada.

DISCLOSURES

Olivia Samotus reports grants from MITACS (Merz Pharma), during the conduct of the study.

Mandar Jog reports grants from Merz Pharma, Allergan Inc, Teva Pharmaceuticals, and Abbvie during the conduct of the study. Dr. Jog also reports the following disclosures: grant from Boston Scientific; personal fees received from Ipsen; a grant from Medtronic; personal fees received from MDDT Inc.; and personal fees received from Novartis. In addition, he has a patent (no. PCT/CA2013/000804) pending to MDDT Inc. and a patent (no. PCT/CA2014/050893) pending to MDDT Inc.

Niraj Kumar and Philippe Rizek have nothing to disclose.

FUNDING

The present study was partially funded by a research grant from Merz Pharma Canada and a government/industry matched grant from MITACS (no. IT03924) in partnership with Merz Pharma. Merz Pharma (www.merzcanada.com; grant no. R.14.022) provided funding for this investigator-initiated trial. Dr. Jog’s role included study design and supervision, treatment administration, and preparation and decision to publish the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to CJNS policies on sharing data and materials.

STATEMENT OF AUTHORSHIP

Study concept and design: Mandar Jog.
Study supervision and coordination: Olivia Samotus, Mandar Jog.
Writing/revising content of manuscript: Olivia Samotus, Philippe Rizek, Niraj Kumar, Mandar Jog.
Analysis and interpretation of data: Olivia Samotus, Philippe Rizek, Niraj Kumar, Mandar Jog.
Statistical analysis: Olivia Samotus.
Obtaining funding: Mandar Jog.

SUPPLEMENTARY MATERIAL

To view the supplementary materials for this article, please visit https://doi.org/10.1017/cjn.2017.260

REFERENCES